Obeticholic Acid: First Global Approval.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Obeticholic acid (Ocaliva(TM)) is a farnesoid-X receptor (FXR) agonist that is being developed by Intercept Pharmaceuticals for the treatment of various liver diseases, and has recently been granted accelerated approval in the USA for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid. The drug is in preregistration for this indication in the EU. This article summarizes the milestones in the development of obeticholic acid leading to this first approval for primary biliary cholangitis.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Drugs

Title: Drugs

Publisher: Springer Nature

ISSN (Electronic): 1179-1950

ISSN (Print): 0012-6667

Publication date (Electronic): Aug 2016

Volume: 76

Issue: 12

Affiliations

[1 ] Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand.

[2 ] Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.

Article

Publisher Item ID: 10.1007/s40265-016-0616-x

DOI: 10.1007/s40265-016-0616-x

PubMed ID: 27406083

SO-VID: 0070fa48-e9b0-4266-a113-120ad4d0febd

History

Data availability:

Comments

Comment on this article

scite_

Cited by 29

See all cited by